Status:
UNKNOWN
Immunogenicity of After Primary Immunization and Booster Immunization of sIPV
Lead Sponsor:
Sinovac Biotech Co., Ltd
Collaborating Sponsors:
Jiangxi Center for Disease Control and Prevention
Conditions:
Polio
Eligibility:
All Genders
2-27 years
Brief Summary
This study was conducted on the basis of "Safety Observation of Sabin Strain Inactivated Polio Vaccine (Vero Cell) on primary Immunization, Booster Immunization and Simultaneous Vaccination with Other...
Eligibility Criteria
Inclusion
- Participated in the previous study (ID: PRO-sIPV-MA4001-JX)
- Subjects in the Primay immunization group(aged 2-3 months) need to complete 3 doses of sIPV vaccination, and the simultaneous vaccination group DTaP needs to complete 3 doses of vaccination; the booster immunity group(aged more than 18 months) needs to complete sIPV vaccination, and the simultaneous vaccination group needs to complete the corresponding vaccination;
- There should be an interval of 1-9 months between the last dose of vaccination and the date of blood sample collection;
- The guardian of subjects need to agree to sign the informed consent form.
Exclusion
- The interval between vaccination and blood collection is less than 1 month, or more than 9 months;
- Subjects were participating in other clinical studies of vaccines or drugs;
- Other conditions that make subjects unsuitable for participating in this study judged by investigator's
Key Trial Info
Start Date :
August 16 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
233 Patients enrolled
Trial Details
Trial ID
NCT06058429
Start Date
August 16 2023
End Date
December 31 2023
Last Update
October 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jiangxi Center for Disease Control and Prevention
Nanchang, Jiangxi, China, 330029